QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,870 signal articles · 534 in last 24h · 105,987 total before filter · latest 46m ago
534last 24h
2496last 7d
493● bullish (7d)
255● bearish (7d)
200publishers
AllMacro167Earnings1553M&A142Regulatory15Product8Analyst23
✕ clear all filtersticker: GESentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Analysts See 24% Upside To GE Aerospace (GE)
Insider Monkey92d agoneutral
Analysts See 24% Upside To GE Aerospace (GE)

GE Aerospace (NYSE:GE) is among the 10 Best Large Cap Defense Stocks to Buy According to Hedge Funds. As of the close of business on May 5, the stock is a consensus Strong Buy, with an average upside potential of 24% based on 13 analysts’ recommendations. Recent updates include Jefferies trimming its price target on […]

Is It Too Late To Consider General Electric (GE) After Its Strong Multi Year Rally?
Simply Wall St.93d agobullish
Is It Too Late To Consider General Electric (GE) After Its Strong Multi Year Rally?

Wondering if General Electric's share price still offers value after a strong run, or if most of the upside is already reflected in the stock. At a last close of US$280.52, the stock has seen a 1.4% decline over the past week and is roughly flat over 30 days. Longer term returns of 35.0% over 1 year and 254.1% over 3 years, plus a very large 5 year gain, highlight how different time frames tell very different stories about risk and reward. Recent coverage has focused on how General Electric...

1 High-Flying Stock to Target This Week and 2 We Find Risky
StockStory93d agoneutral
1 High-Flying Stock to Target This Week and 2 We Find Risky

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.

Jim Cramer Says “This Is a Good Moment to Buy” GE Aerospace
Insider Monkey97d agobullish
Jim Cramer Says “This Is a Good Moment to Buy” GE Aerospace

GE Aerospace (NYSE:GE) was among Jim Cramer’s stock calls on Mad Money recently as he recapped mega-cap tech earnings. A caller sought Cramer’s opinion of the stock, and in response, he said: I think you should buy it right here. Enough is enough. It’s been going down because people are worried about air travel. I […]

GE Aerospace Faces Rare Earth Reset As U.S. Rules Tighten
Simply Wall St.98d agoneutral
GE Aerospace Faces Rare Earth Reset As U.S. Rules Tighten

U.S. procurement rules will prohibit Chinese origin rare earth materials in defense applications from January 2027. China currently supplies a large share of global rare earth alloys used in aerospace engines and components. Domestic U.S. rare earth projects are scaling up to supply companies such as GE Aerospace, part of General Electric (NYSE:GE). General Electric (NYSE:GE), trading at $283.57, sits at the center of this supply chain reset through its GE Aerospace business, which depends...

GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip
24/7 Wall St.98d agobearish
GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip

GE HealthCare (NASDAQ: GEHC) currently trades at $59.49, well below the Wall Street consensus price target of $89.74. That implies upside of roughly 50.8% if the analysts are right. GE HealthCare is the medical imaging and diagnostics business spun from General Electric, with about $20.6 billion in annual revenue across Advanced Imaging Solutions, Patient Care ... GE HealthCare Just Crashed 13% on a Guidance Cut. Here’s the Case for Buying the Dip

GE HealthCare Technologies Q1 Earnings Call Highlights
MarketBeat99d agoneutral
GE HealthCare Technologies Q1 Earnings Call Highlights

GE HealthCare Technologies (NASDAQ:GEHC) reported first-quarter 2026 results that management said landed at the high end of expectations on revenue, while profits and cash flow guidance for the full year were reduced to reflect higher input costs and a first-quarter supplier-related recall in Pharma